LaMontagne, Kenneth R <br/><br/>
A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo.  [electronic resource] 

 -  Angiogenesis  2009 
 - 287-96 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1573-7209 
<br/><br/><label>Standard No.: </label>10.1007/s10456-009-9151-7  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Angiogenesis Inhibitors--administration & dosage<br/>Animals<br/>Cell Movement--drug effects<br/>Cells, Cultured<br/>Endothelial Cells--drug effects<br/>Female<br/>HCT116 Cells<br/>Humans<br/>Mice<br/>Mice, Inbred C57BL<br/>Mice, Nude<br/>Mice, Transgenic<br/>Models, Biological<br/>Neoplasms--drug therapy<br/>Oximes--administration & dosage<br/>Phenylurea Compounds--administration & dosage<br/>Protein Kinase Inhibitors--administration & dosage<br/>Substrate Specificity<br/>Vascular Endothelial Growth Factor A--pharmacology<br/>Vascular Endothelial Growth Factor Receptor-2--antagonists & inhibitors<br/>Xenograft Model Antitumor Assays